T
Overview
Tabula Bioscience uses machine learning to improve disease prediction and personalized medicine. Its core product aims to design programmable, strain-specific antimicrobials that target bacteria via bacteriophages, with R&D focused on phage therapy and gram-negative bacteria. The models leverage unlabeled genomic data from humans and other species, incorporate expert priors and epigenetic information, and use probabilistic programming to build mechanistic biological explanations. The goal is to narrow the gap between heritability and prediction to enable more effective, individualized treatments.
Work here?Claim your company
Simplify's Take
What believers are saying
- August 2026 site says Tabula is treating real patients six months after launch.
- 2026 hiring shows active Madison phage R&D on E. coli, Pseudomonas, and NGS.
- Investors include George Church, Michael Seibel, Emmett Shear, Maven Ventures, and Version One.
What critics are saying
- PitchBook still shows only a 2022 $2M seed, signaling thin capitalization.
- Tabula’s 2026 job ads target temporary bench labor, not scaled manufacturing.
- One failed clinical run in 2026-2027 ends Tabula’s financing and platform credibility.
What makes Tabula unique
- Ammon Bartram and Michael Poon combine Triplebyte, Twitch, MIT, and polygenic-screening experience.
- Tabula’s August 2026 site claims AI designs DNA for individual human infections.
- Forward BIOLABS lists Tabula as a precision antimicrobial therapy startup.
Help us improve and share your feedback! Did you find this helpful?